Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALiBRe: Mechanism of Action of Idelalisib in B-cell Receptor Pathway Inhibition in CLL
2012-003631-36Phase 2Unknown
- Sponsor
- University of Birmingham
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of idelalisib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by University of Birmingham. Primary endpoint: MRD-negative remission rate. Status: unknown.
02
Drugs
idelalisib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2012-003631-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003631-36.